Lorcaserin

Generic Name: Lorcaserin

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₁H_₁₄ClN

CAS Number: 616202-92-7

Unique Ingredient Identifier: 637E494O0Z

Background: Lorcaserin (previously APD-356), a highly selective 5HT2C receptor agonist, is used for the treatment of obesity. It has been shown to reduce body weight and food intake in animal models of obesity, and it is thought that targeting the 5HT2C receptor may alter body weight by regulating satiety. Lorcaserin is marketed as a salt form called Belviq, which is lorcaserin hydrochloride.

In February 2020, the FDA issued a Drug Safety Communication requesting the manufacturer of Belviq (lorcaserin hydrochloride tablets, 10 mg) and Belviq XR (lorcaserin hydrochloride extended-release tablets, 20 mg) to voluntarily withdraw these products from the U.S. market, and the company has submitted a request to voluntarily withdraw the drug. This decision was based on the results of a clinical trial assessing the risk of heart-related problems that found that patients treated with lorcaserin may have a higher risk of cancer.

Indication: For the treatment of obesity, as an adjunct to a reduced-calorie diet and increased physical activity.

Associated Conditions: Obesity

Associated Therapies: -

Clinical Trials

Lorcaserin for Preventing Weight Gain Among Smokers

Phase 1

Completed

Conditions: Weight Gain
Tobacco Use Disorder

Interventions: Drug: Varenicline
Drug: Lorcaserin

First Posted Date: 2015-03-19

Last Posted Date: 2017-06-06

Lead Sponsor: Mayo Clinic

Target Recruit Count: 20

Registration Number: NCT02393547

Locations: 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

Lifestyle Modification and Lorcaserin for Weight Loss Maintenance

Not Applicable

Completed

Conditions: Obesity

Interventions: Drug: Lorcaserin
Drug: Placebo

First Posted Date: 2015-03-17

Last Posted Date: 2018-06-11

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 137

Registration Number: NCT02388568

Locations: 🇺🇸
University of Pennsylvania Center for Weight and Eating Disorders, Philadelphia, Pennsylvania, United States

Low Level Laser Treatment (LLLT) and Lorcaserin for Weight Management

Phase 3

Completed

Conditions: Overweight
Obese

Interventions: Device: LLLT
Drug: Lorcaserin

First Posted Date: 2014-05-02

Last Posted Date: 2016-11-22

Lead Sponsor: Mayo Clinic

Target Recruit Count: 44

Registration Number: NCT02129608

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Single Dose Study to Determine the Safety, Tolerability, and Pharmacokinetic Properties of Lorcaserin Hydrochloride (BELVIQ) in Obese Adolescents From 12 to 17 Years of Age

Phase 1

Completed

Conditions: Pharmacokinetics in Obese Adolescents

Interventions: Drug: Lorcaserin

First Posted Date: 2013-12-30

Last Posted Date: 2019-09-17

Lead Sponsor: Eisai Inc.

Target Recruit Count: 8

Registration Number: NCT02022956

Locations: 🇺🇸
Worlwide Clinical Trials, San Antonio, Texas, United States
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States